SkinVision
SkinVision is a European health technology company that develops CE-marked AI-powered mobile applications for skin cancer risk detection, serving individual consumers through a subscription app and healthcare providers via its SkinVision Pro B2B platform.
- Company typePrivate
- Founded2012
- HeadquartersAmsterdam, Netherlands
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What SkinVision does
SkinVision is a European health technology company founded in 2012 and headquartered in Amsterdam, Netherlands, that develops AI-powered mobile applications for skin cancer risk detection. The company operates a dual-product portfolio: a direct-to-consumer SkinVision App that allows individuals to photograph skin lesions and receive AI-generated risk indications, and SkinVision Pro, a B2B platform launched at HLTH Europe in 2026 that delivers AI-analyzed skin assessments directly to medical practices, providing doctors with structured patient information before consultations begin. The underlying technology is a computer vision pipeline trained on skin imagery, achieving clinically validated accuracy exceeding 90% sensitivity and 89% specificity for skin cancer detection, and holds CE marking as a Class IIa medical device in Europe.
SkinVision generates revenue through subscription-based models across both consumer and healthcare-provider segments. The consumer app targets individuals seeking accessible skin health monitoring and early detection, addressing pain points such as limited dermatology access and wait times of up to six months across health systems. SkinVision Pro targets healthcare providers, dermatology practices, and primary care networks as a triage solution, with early Dutch primary care data demonstrating 80% low-risk patient reassurance at home and 24% confirmed skin cancer diagnoses among high-risk patients. US market entry is pending FDA authorization, supported by a pivotal clinical trial partnership with Mayo Clinic announced in March 2026.
The company has raised approximately $16.5 million across eight funding rounds since inception, with strategic backing from Rubio Impact Ventures, LEO Pharma, and PHS Capital. SkinVision operates with 11-50 employees, a leadership team including CEO Erik de Heus and founder Victor Anastasiu, and is currently active in Europe while preparing for geographic expansion into the United States.
SkinVision firmographics
Firmographics- Name
- SkinVision
- Legal name
- SkinVision
- Website
- https://skinvision.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SkinVision is a European health technology company that develops CE-marked AI-powered mobile applications for skin cancer risk detection, serving individual consumers through a subscription app and healthcare providers via its SkinVision Pro B2B platform.
- Ownership category
- akta.pro rank
SkinVision industry classification
Industry- Product category
- AI Dermatology Software
- akta.pro primary industry
- Dermatology Telemedicine Platforms (HLALAGAA)
- akta.pro secondary industries
- Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices) (CRABAAAJ), Medical-Grade / Clinical Facials (Dermatology & Med Spa) (HSALADAN)
Keywords
Where SkinVision is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
SkinVision business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Consumer App Subscriptions: Mobile application offering skin health assessments to individual consumers, likely subscription-based model for ongoing monitoring and assessments.
- Healthcare Provider Solutions (SkinVision Pro): B2B platform connecting AI skin assessments to medical practices and clinics, providing structured patient data before consultations.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
SkinVision product offering
Product offeringCore offering
SkinVision develops AI-powered skin health assessment technology delivered through a consumer-facing mobile application (SkinVision App) and a B2B platform (SkinVision Pro) that connects AI-analyzed skin assessments directly to medical practices. The technology uses computer vision algorithms on skin images to detect potential skin cancer with clinically validated accuracy of over 90% sensitivity and 89% specificity, and is CE-marked as a Class IIa medical device.
Product overview
SkinVision offers a dual-product portfolio consisting of the SkinVision App for consumer-facing skin health assessment and SkinVision Pro for healthcare provider integration. The SkinVision App enables individual users to conduct skin assessments and receive AI-powered risk indications, while SkinVision Pro connects these assessments directly to medical practices, giving doctors structured patient information before consultations begin. Both offerings are backed by the same clinically validated AI technology achieving over 90% sensitivity and 89% specificity for skin cancer detection.
Differentiator
Problem solved
Functional benefit
Brands
- SkinVision Pro: AI-powered skin health platform that connects assessments directly to medical practices and clinics before consultations begin, providing doctors with structured patient information.
Products and services
- SkinVision App Health technology mobile application that enables individuals to assess skin conditions using smartphone-captured images, providing AI-powered risk indications to support early skin cancer detection and ongoing skin monitoring over time. Targeted at individual consumers in Europe.
- SkinVision Pro B2B platform that connects AI-powered skin health assessments directly to medical practices and clinics, providing doctors with structured patient information before consultations begin. Targeted at healthcare providers, dermatologists, and primary care practices across Europe.
Quantifiable outcome
- Over 90% sensitivity and 89% specificity for skin cancer detection
- +2 more outcomes
Companies that use SkinVision
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
SkinVision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature2 records
SkinVision partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mayo CliniccoreSkinVision has partnered with Mayo Clinic to conduct a pivotal clinical trial in the United States. The study aims to evaluate the app's performance and support FDA approval of its AI-based skin assessment app. This partnership represents a significant clinical validation opportunity and pathway to the US market, addressing rising skin cancer cases and systemic healthcare barriers.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
SkinVision competitors and assessment
Company assessmentDirect peers
- Miiskin: Consumer-facing app for tracking moles and skin changes over time using smartphone photography. Comparable D2C GTM and skin-monitoring use case, though positioned for self-monitoring rather than regulatory-grade triage.
- MetaOptima (MoleScope / DermEngine): Developer of MoleScope (consumer dermatoscope attachment) and DermEngine (AI dermatology platform for clinicians). Comparable across both the consumer imaging and clinician AI-triage segments SkinVision serves.
- Skin Analytics: UK-based AI dermatology platform offering similar clinical-grade skin cancer triage to GPs and dermatologists. Closest direct comparable: same technology category, same regulatory pathway (UKCA / CE), same provider-segment GTM.
- iDoc24: European tele-dermatology service offering app-based image submission for dermatologist review within 24 hours. Comparable target customer (skin-aware consumer) and regulatory jurisdiction, with a human-in-the-loop rather than AI-first model.
- DermaSensor: US-based developer of an FDA-cleared AI-enabled point-of-care skin cancer evaluation device for primary care physicians. Comparable AI-triage product targeting the same dermatologist-shortage problem; provides a US regulatory benchmark for SkinVision's FDA pathway.
- First Derm: Tele-dermatology platform connecting users to dermatologists for asynchronous image-based consultations. Adjacent GTM (skin image → remote clinician triage) and overlapping user base, but uses human clinicians rather than AI for triage.
Broad incumbents
- Teladoc Health: Large-scale telemedicine provider offering dermatology among many other virtual care specialties. Indirectly comparable as a tele-dermatology access channel for consumers and a platform partner / potential competitor for SkinVision Pro provider deployments.
- VisualDx: Clinical decision support platform covering dermatology among other specialties, used by physicians for differential diagnosis. Comparable AI/visual-diagnostic technology stack, broader specialty footprint, and provider-segment sales motion.
- DermAssist (Google Health): Google's AI dermatology assistant that lets consumers photograph skin conditions for triage. Comparable product and target user, but bundled within a broader consumer health portfolio and backed by Google's distribution and data resources.
- FotoFinder Systems: Established German manufacturer of total body photography and AI-assisted dermoscopy systems used by dermatology clinics. Comparable clinical imaging and AI-triage category, but a hardware-centric incumbent rather than a smartphone-software-native play.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
SkinVision social profiles
Digital presenceSkinVision compliance and trust
Trust signalCompliance1 record
SkinVision financial estimates
Financial estimateRevenue estimate
Valuation estimate
SkinVision leadership team
Management profileNumber of profiles
Profiles8 records
SkinVision funding detail
Funding detailFunding overview
Funding rounds8 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SkinVision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SkinVision
What does SkinVision do?
SkinVision develops AI-powered skin health assessment technology delivered through a consumer-facing mobile application (SkinVision App) and a B2B platform (SkinVision Pro) that connects AI-analyzed skin assessments directly to medical practices. The technology uses computer vision algorithms on skin images to detect potential skin cancer with clinically validated accuracy of over 90% sensitivity and 89% specificity, and is CE-marked as a Class IIa medical device.
Is SkinVision a public or private company?
SkinVision is a private company. It is classified as venture growth investor backed and is currently operating.
When was SkinVision founded?
SkinVision was founded in 2012. It employs 11 to 50 people.
Where is SkinVision based?
SkinVision is headquartered in Amsterdam, Netherlands, in the Europe region.
How does SkinVision make money?
Two revenue lines are on record. Consumer App Subscriptions are the primary driver. The others are healthcare Provider Solutions (SkinVision Pro).
Who are SkinVision's main competitors?
Direct peers on record are Miiskin, MetaOptima (MoleScope / DermEngine), Skin Analytics, iDoc24, DermaSensor and First Derm. Broad incumbents are Teladoc Health, VisualDx, DermAssist (Google Health) and FotoFinder Systems.
Does SkinVision have an API?
No public API is recorded for SkinVision.
What industry is SkinVision in?
SkinVision's product category is AI Dermatology Software. Its primary akta.pro industry code is HLALAGAA, Dermatology Telemedicine Platforms, with a secondary code of CRABAAAJ, Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices).